A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

Inclusion Criteria:

* Men or women ≥ 18 years of age
* Must have a pathologically documented, and definitively diagnosed, advanced solid tumor that is refractory to standard treatment, or for which no curative therapy is available, or for subjects who refuse standard therapy
* Evaluable OR measurable disease by RECIST 1.1 criteria
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
* Life expectancy of \> 3 months, in the opinion of and as documented by the investigator
* Subject or subject's legally acceptable representative has provided informed consent

Exclusion Criteria:

* Subjects with gastric cancer or any malignancy with purely squamous cell histology
* Known history of primary central nervous system (CNS) tumors or CNS metastases
* Myocardial infarction within 1 year before study day 1, unstable or uncontrolled disease/condition related to or affecting cardiac function (eg, unstable angina, congestive heart failure, New York Heart Association \> class II, uncontrolled hypertension \[diastolic \> 90 mmHg; systolic \> 150 mmHg in repeated measurements\])
* History of stroke, arterial or venous thrombosis, or pulmonary embolism within 1 year before study day 1
* Active grade 2 or greater peripheral vascular disease or peripheral edema
* History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis)
* Non-healing wound, ulcer (including gastrointestinal) or fracture
* Known positive test for human immunodeficiency virus infection, or active hepatitis B or hepatitis C infection
* Major surgery within 4 weeks before study day 1
* Absolute neutrophils count (ANC) \< 1.0 x 10\^9/L; or platelet count \< 100 x 10\^9/L; or hemoglobin \< 9 g/dL; or PTT / aPTT \> 1.5 x institutional upper limit of normal (ULN) ); or INR \> 1.5
* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2.5 x ULN (\> 5.0 x ULN if liver metastases present)
* Alkaline phosphatase \> 2.5 x ULN (\> 5.0 x ULN if attributable to liver or bone metastasis)
* Total bilirubin \> 1.5 x ULN
* Other investigational procedures during the study
* Previous anti-cancer therapy or investigational agent within 4 weeks prior to study day 1
* Anticoagulation therapy within 4 weeks of study day 1 and while on study (except low dose warfarin (≤ 2 mg/kg) for prophylaxis against central venous catheter thrombosis)
* Men and women of reproductive potential, unwilling to practice a highly effective method of birth control for the duration of the study and an additional 6 months after the last dose of AMG 386. Highly effective methods of birth control include sexual abstinence (men, women); vasectomy or a condom with spermicide (men) in combination with barrier methods, hormonal birth control or IUD (women).
* Women who are lactating/breastfeeding.
* Women with a positive pregnancy test.